Navigation Links
Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
Date:2/14/2008

EMERYVILLE, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss fourth quarter and full year 2007 financial results and provide a business overview on Tuesday, February 19, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the fourth quarter and year ended December 31, 2007 will be released earlier that day.

Interested parties may access a live webcast of the presentation at: http://webcast.streamlogics.com/audience/index.asp?eventid=62782 or by dialing 847-413-3238 and using the passcode 20350141. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 20350141 approximately one hour after the teleconference concludes. The replay will be available through March 19, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and for the treatment of liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer and other tumor types. For more information about Onyx, visit the company's website at: http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered t
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vion Pharmaceuticals Holds Special Meeting of Stockholders
3. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
4. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
5. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
6. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
10. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):First-in-class treatment for acute leukemia 2First-in-class treatment for acute leukemia 3Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3Researchers demonstrate nanoscale X-ray imaging of bacterial cells 2Single Moms Clever Idea 3A Kill Head Lice With Salt 56133 1Single Moms Clever Idea 3A Kill Head Lice With Salt 56133 2Single Moms Clever Idea 3A Kill Head Lice With Salt 56133 3Encap agrees colonic drug delivery licensing deal 9775 1Encap agrees colonic drug delivery licensing deal 9775 2Encap agrees colonic drug delivery licensing deal 9775 3PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 1PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 2PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 3PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 4PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 5PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 6PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 7PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 8PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 9